Europese Unie - Nederlands - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, type 2 - geneesmiddelen die worden gebruikt bij diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , drievoudige combinatietherapie) als aanvulling op dieet en lichaamsbeweging bij patiënten die onvoldoende gecontroleerd op hun maximale getolereerde dosis van metformine en een enz.). sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europese Unie - Nederlands - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, type 2 - geneesmiddelen die worden gebruikt bij diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , drievoudige combinatietherapie) als aanvulling op dieet en lichaamsbeweging bij patiënten die onvoldoende gecontroleerd op hun maximale getolereerde dosis van metformine en een enz.). sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europese Unie - Nederlands - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, type 2 - geneesmiddelen die worden gebruikt bij diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

joint stock company grindeks - sitagliptinehydrochloridemonohydraat 28,35 mg - eq. sitagliptine 25 mg - filmomhulde tablet - 25 mg - sitagliptinehydrochloridemonohydraat 28.35 mg - sitagliptin

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

joint stock company grindeks - sitagliptinehydrochloridemonohydraat 56,7 mg - eq. sitagliptine 50 mg - filmomhulde tablet - 50 mg - sitagliptinehydrochloridemonohydraat 56.7 mg - sitagliptin

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

joint stock company grindeks - sitagliptinehydrochloridemonohydraat 113,4 mg - eq. sitagliptine 100 mg - filmomhulde tablet - 100 mg - sitagliptinehydrochloridemonohydraat 113.4 mg - sitagliptin

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

hetero europe s.l. viladecans business park, edificio brasil, catalunya 83-85 08840 viladecans (spanje) - sitagliptinehydrochloride 113,4 mg/stuk samenstelling overeenkomend met ; sitagliptinehydrochloride 109 mg/stuk - filmomhulde tablet - calciumwaterstoffosfaat 0-water (e 341) ; cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; ijzeroxide geel (e 172) ; ijzeroxide rood (e 172) ; macrogol 4000 ; magnesiumstearaat (e 470b) ; natriumstearylfumaraat ; polyvinylalcohol, gedeeltelijk gehydrolyseerd (e1203) ; talk (e 553 b) ; titaandioxide (e 171) ; samenstelling overeenkomend met sitagliptine, calciumwaterstoffosfaat 0-water (e 341) ; cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; ijzeroxide geel (e 172) ; ijzeroxide rood (e 172) ; macrogol 3350 ; magnesiumstearaat (e 470b) ; natriumstearylfumaraat ; polyvinylalcohol, gedeeltelijk gehydrolyseerd (e1203) ; talk (e 553 b) ; titaandioxide (e 171) - sitagliptin

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

hetero europe s.l. viladecans business park, edificio brasil, catalunya 83-85 08840 viladecans (spanje) - sitagliptinehydrochloride 1-water 56,7 mg/stuk samenstelling overeenkomend met ; sitagliptinehydrochloride 54,5 mg/stuk - filmomhulde tablet - calciumwaterstoffosfaat 0-water (e 341) ; cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; ijzeroxide geel (e 172) ; ijzeroxide rood (e 172) ; macrogol 4000 ; magnesiumstearaat (e 470b) ; natriumstearylfumaraat ; polyvinylalcohol, gedeeltelijk gehydrolyseerd (e1203) ; talk (e 553 b) ; titaandioxide (e 171) ; samenstelling overeenkomend met sitagliptine, calciumwaterstoffosfaat 0-water (e 341) ; cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; ijzeroxide geel (e 172) ; ijzeroxide rood (e 172) ; macrogol 3350 ; magnesiumstearaat (e 470b) ; natriumstearylfumaraat ; polyvinylalcohol, gedeeltelijk gehydrolyseerd (e1203) ; talk (e 553 b) ; titaandioxide (e 171) - sitagliptin

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - sitagliptinehydrochloridemonohydraat 28,343 mg - eq. sitagliptine 25 mg - filmomhulde tablet - 25 mg - sitagliptinehydrochloridemonohydraat 28.343 mg - sitagliptin

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - sitagliptinehydrochloridemonohydraat 56,685 mg - eq. sitagliptine 50 mg - filmomhulde tablet - 50 mg - sitagliptinehydrochloridemonohydraat 56.685 mg - sitagliptin